New biomarkers predict outcome of cancer immunotherapy

January 8, 2018, University of Zurich

Researchers at the University of Zurich have identified biomarkers in the blood that make it possible to predict whether cancer patients will respond positively to immunotherapy. Pa-tients for whom therapy does not work can thus be treated using different methods at an earlier stage.

Nowadays, melanoma and lung can be combatted effectively through immunotherapy, which makes targeted use of the immune system's normal function of regularly examining the body's tissue for pathogens and damages. Specific inhibitors are used to activate in a way that makes them identify as foreign bodies and eliminate them. This way, the immune system can boost its often weak immune response to allow it to even detect and destroy metastatic cancer . Immunotherapy thus makes it possible to control cancer cells in up to 50 percent of patients, in some cases even curing them altogether.

Not all respond to immunotherapy

However, around half of do not respond to immunotherapy, but still have to put up with its side effects. A team of researchers from the University of Zurich and the UniversityHos-pital Zurich has now used a novel method to find out which patients are likely to respond positive-ly to immunotherapy. The researchers were able to identify biomarkers in the blood that indicate whether the therapy is highly likely to be effective even before treatment is commenced.

"The blood counts of patients should be analyzed for these biomarkers when making a decision about immunotherapy. This will dramatically increase the share of patients who will benefit from this type of therapy," says Professor Burkhard Becher from the Institute of Experimental Immunol-ogy at UZH. "At the same time, it makes it possible to directly move on to different methods in cases where immunotherapy won't work - without losing valuable time."

High-dimensional cell analysis

The researchers worked hand in hand with the Department of Dermatology of the UniversityHospi-tal Zurich to examine biomarkers in 40 blood samples of 20 , both before and 12 weeks after . For this, they used the high-dimensional "cytometry by time of flight" (Cy-TOF) cell analysis method, which analyzes cells for up to 50 different proteins one cell at a time. The researchers were thus able to differentiate every single cell and document its activation sta-tus. Even nuanced differences between the patient samples were recorded in detail.

Recognizing molecular patterns

After analyzing the cells, the researchers examined the data together with employees of the Swiss Institute of Bioinformatics at UZH in terms of molecular patterns that could predict therapeu-tic success. "Even before the start of a therapy, we observed a subtle and weak immune re-sponse in the blood, and identified this molecular pattern as the immune cells CD14+CD16−HLA-DRhi," says Burkhard Becher. For the finding to be easily verifiable, the should be easi-ly detectable; indeed, the count was able to be validated using conventional methods in a second, independent cohort of more than 30 people.

Dawning of precision medicine

"Together with comprehensive, precisely structured biobanking, this study represents a major step towards precision medicine," says Professor Mitch Levesque of the Department of Dermatology at the UniversityHospital Zurich. Before they can be used clinically, the insights gained must now be applied in independent studies with higher patient numbers. The method using biobanking, high-dimensional cytometry, and computer-aided pattern recognition should also be useful in clinical decision support and developing new therapeutic approaches when it comes to other clinical pictures.

Explore further: Molecular profiling of melanoma tumours explains differences in survival after T cell therapy

More information: Carsten Krieg, Malgorzata Nowicka, Silvia Guglietta, Sabrina Schindler, Felix J Hartmann, Lukas M Weber, Reinhard Dummer, Mark D Robinson, Mitchell P Levesque & Burkhard Becher. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nature Medicine, 8 January 2018. DOI: 10.1038/nm.4466

Related Stories

Molecular profiling of melanoma tumours explains differences in survival after T cell therapy

November 28, 2017
The more times metastasised melanoma has mutated and the patient's immune system has been activated against the tumour – the better the chances of survival after immunotherapy. This is what emerges from a research collaboration ...

White blood cell count predicts response to lung cancer immunotherapy

May 4, 2017
White blood cell counts can predict whether or not lung cancer patients will benefit from immunotherapy, according to research presented at the European Lung Cancer Conference (ELCC).

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Rush clinical trial provides new kidney cancer immunotherapy option

May 19, 2017
Rush University Medical Center is among the first hospitals in the nation, and the only one in Illinois, to provide patients fighting advanced kidney access to a new combination immunotherapy that targets different immune ...

DNA mutations shed in blood predicts response to immunotherapy in patients with cancer

October 2, 2017
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.

Protein may predict response to immunotherapy in patients with metastatic melanoma

May 5, 2016
A protein called Bim may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma, according to the results of a study by Mayo Clinic researchers led by senior author Haidong Dong, M.D., ...

Recommended for you

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Shakescene21
not rated yet Jan 08, 2018
Precision medicine. In this case a more precise diagnosis which allows the patient to receive the most appropriate treatment. Not only are outcomes better for the patients, but this should create cost savings since useless and destructive treatments aren't wasted on the wrong patients.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.